Company Shares of St. Jude Medical Drops by -1.18%

St. Jude Medical (NYSE:STJ) has tumbled 1.18% during the past week and has dropped 0.44% in the last 4 week period. The company has outperformed the S&P 500 by 0.01% in the past week but underperformed the index by 1.35% in the last 4 weeks.

St. Jude Medical (NYSE:STJ): The stock opened at $76.63 on Friday but the bulls could not build on the opening and the stock topped out at $76.77 for the day. The stock traded down to $76.41 during the day, due to lack of any buying support eventually closed down at $76.44 with a loss of -0.38% for the day. The stock had closed at $76.73 on the previous day. The total traded volume was 4,530,758 shares.

The company shares have rallied 1.03% from its 1 Year high price. On Jul 21, 2015, the shares registered one year high at $80.84 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $76.80 and the 200 Day Moving Average price is recorded at $61.94.

On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (VP, Global Quality) of St Jude Medical Inc, Fecho Jeff had sold 10,408 shares worth of $538,198 in a transaction dated February 5, 2016. In this transaction, 10,408 shares were sold at $51.71 per share.

Many analysts have stated their opinion on the company shares. Brokerage firm Barclays downgrades its rating on St. Jude Medical (NYSE:STJ). As per the latest information, the brokerage house raises the price target to $80 per share from a prior target of $74. The shares have been rated Equal-weight. Previously, the analysts had a Overweight rating on the shares. The rating by the firm was issued on May 11, 2016. Currently the company Insiders own 4.8% of St. Jude Medical shares according to the proxy statements. Institutional Investors own 85.37% of St. Jude Medical shares.

St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems, bradycardia pacemaker systems, atrial fibrillation (AF) products (electrophysiology introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems), vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, heart failure monitoring device and other vascular accessories), structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).

Leave a Reply

Annabelle Begley - Is it time to Sell?

Top Brokerage Firms are advising their investors on Annabelle Begley. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.